CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck CancerBusiness Wire • 07/11/23
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be FiledBusiness Wire • 06/22/23
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023Business Wire • 05/15/23
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common StockBusiness Wire • 04/28/23
CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment of Head & Neck CancerBusiness Wire • 04/19/23
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck OncologyBusiness Wire • 03/03/23
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/28/22
CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care TreatmentBusiness Wire • 10/17/22
CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The HorizonSeeking Alpha • 09/30/22
CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck CancerBusiness Wire • 09/12/22
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.govBusiness Wire • 08/19/22
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/22/21